Stockscreener 앱 받기
35.68
0.24%
-0.09
전일 마감가:
$35.77
열려 있는:
$35.57
하루 거래량:
130.52K
Relative Volume:
0.19
시가총액:
$1.55B
수익:
$384.10M
순이익/손실:
$-9.07M
주가수익비율:
-254.86
EPS:
-0.14
순현금흐름:
$11.10M
1주 성능:
-1.50%
1개월 성능:
+6.91%
6개월 성능:
+55.35%
1년 성능:
+40.55%
1일 변동 폭
$35.41
$35.98
1주일 범위
$35.41
$37.34
52주 변동 폭
$17.82
$37.34
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
명칭
Kiniksa Pharmaceuticals International Plc
전화
(781) 431-9100
주소
23 OLD BOND STREET, FLOOR 3, LONDON
KNSA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
35.68 | 2.65B | 384.10M | -9.07M | 11.10M | -0.14 |
|
ZTS
Zoetis Inc
|
147.15 | 65.35B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.14 | 47.75B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.40 | 41.52B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.39 | 21.43B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
403.98 | 18.00B | 2.99B | 1.21B | 1.13B | 25.06 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-09-13 | 개시 | Jefferies | Buy |
| 2024-05-03 | 개시 | Wells Fargo | Overweight |
| 2020-06-29 | 재확인 | BofA Securities | Buy |
| 2020-04-01 | 개시 | BofA/Merrill | Buy |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-12-12 | 재확인 | Wedbush | Outperform |
| 2018-06-19 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Kiniksa Pharmaceuticals International Plc 주식(KNSA)의 최신 뉴스
Short Interest in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Grows By 29.7% - MarketBeat
Fred Alger Management LLC Makes New Investment in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Holdings Raised by AQR Capital Management LLC - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Shares Purchased by Acadian Asset Management LLC - MarketBeat
Using fundamentals and technicals on Kiniksa Pharmaceuticals Ltd.July 2025 Decliners & Long-Term Growth Plans - newser.com
Kiniksa Pharmaceuticals COO Tessari Eben sells $273,980 in shares - MSN
Backtesting results for Kiniksa Pharmaceuticals Ltd. trading strategiesRisk Management & Free High Accuracy Swing Entry Alerts - newser.com
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Exploring High Growth Tech Stocks in the US Market September 2025 - simplywall.st
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 12-Month HighStill a Buy? - MarketBeat
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider Sells 3,523 Shares of Stock - MarketBeat
Eben Tessari Sells 13,389 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells 85,271 Shares - MarketBeat
American Century Companies Inc. Trims Stake in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Cubist Systematic Strategies LLC Takes $4.66 Million Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Granahan Investment Management LLC Has $8.04 Million Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CAO Michael R. Megna Sells 11,000 Shares - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 12-Month HighWhat's Next? - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Stock Position Boosted by Invesco Ltd. - MarketBeat
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells 15,091 Shares of Stock - MarketBeat
Kiniksa Pharma COO Tessari sells shares worth $3.5m By Investing.com - Investing.com Australia
Kiniksa Pharma: Chief corp officer Moat Ross sells $124k in shares - Investing.com Canada
Kiniksa Pharma COO Tessari sells shares worth $3.5m - Investing.com
Ieq Capital LLC Purchases New Stake in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
169,864 Shares in Kiniksa Pharmaceuticals International, plc $KNSA Purchased by Vestal Point Capital LP - MarketBeat
Corebridge Financial Inc. Buys 549 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - Defense World
Birchview Capital LP Makes New Investment in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Position Lowered by ADAR1 Capital Management LLC - MarketBeat
Trexquant Investment LP Has $5.25 Million Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
PDT Partners LLC Cuts Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Braidwell LP Decreases Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by American Century Companies Inc. - Defense World
Kiniksa Pharmaceuticals International, plc $KNSA Holdings Boosted by Wellington Management Group LLP - MarketBeat
Hsbc Holdings PLC Cuts Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - Defense World
Charles Schwab Investment Management Inc. Has $3.65 Million Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International Plc (KNSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.52%
0.91%
자본화:
|
볼륨(24시간):